首页> 外文期刊>Journal of Enam Medical College >Outcome of Childhood Acute Lymphoblastic Leukaemia after Induction Therapy --- Three-Year Experience in a Tertiary Care Hospital in Bangladesh
【24h】

Outcome of Childhood Acute Lymphoblastic Leukaemia after Induction Therapy --- Three-Year Experience in a Tertiary Care Hospital in Bangladesh

机译:诱导治疗后儿童急性淋巴细胞白血病的结果---孟加拉国三级医院的三年经验

获取原文
       

摘要

Background: The incidence of different malignancies is increasing among the world populations. Acute lymphoblastic leukaemia (ALL) is the most common of all the paediatric malignancies. Response to induction therapy is one of the most important predictors of long term outcome of ALL.Objective: To see the immediate outcome of paediatric ALL patients following induction therapy.Materials and Methods: This retrospective study was conducted from January 2013 to December 2015. Total 221 paediatric ALL patients were included in this study. Diagnosis was based on history, examination, blast cells count on peripheral blood film and bone marrow study, CSF study and immunophenotyping of peripheral blood/bone marrow aspirate in patients who were financially capable. Among them, parents of 40 (18%) patients did not agree to start chemotherapy. According to Modified UK ALL 2003 protocol (Regimen A & B) 181 patients were given induction therapy (vincristine, prednisolone, L-asparaginase, and daunomycin) in high risk patients. Among them 14 patients discontinued, 10 patients died during chemotherapy and rest 157 patients completed induction phase. Bone marrow study was repeated after completion of induction therapy and remission pattern was seen.Results: Out of 157 chemotherapy completed patients, 137 (87%) went into complete remission (<5% blast cells in bone marrow), 14 (9%) into partial remission (5--25% blast cells in bone marrow) and 6 (4%) was not in remission (>25% blast cells in the bone marrow). Ten (5.5%) patients died due to bleeding, febrile neutropenia and sepsis during the course of induction therapy.Conclusion: ALL in children is curable with effective chemotherapy. Poverty, ignorance and misconception regarding outcome are responsible for refusal and discontinuation of chemotherapy in third world countries like Bangladesh. Mortality and treatment cost can be reduced with the improvement of the facilities for isolation, barrier nursing and supportive treatment, and by creating awareness.J Enam Med Col 2017; 7(1): 25-28
机译:背景:世界各地不同恶性肿瘤的发病率正在增加。急性淋巴细胞白血病(ALL)是所有小儿恶性肿瘤中最常见的。对诱导疗法的反应是ALL长期结果的最重要预测指标之一。目的:观察诱导疗法后小儿ALL患者的近期结果。材料与方法:这项回顾性研究于2013年1月至2015年12月进行。这项研究纳入了221名儿科ALL患者。诊断依据是有经济能力的患者的病史,检查,外周血膜上的胚细胞计数和骨髓研究,CSF研究以及外周血/骨髓抽吸物的免疫表型分析。其中,有40名患者(18%)的父母不同意开始化疗。根据修改后的UK ALL 2003方案(A和B方案),对高危患者中的181例患者进行了诱导治疗(长春新碱,泼尼松龙,L-天冬酰胺酶和道诺霉素)。其中停药的14例患者,化疗中死亡的10例患者,其余的157例完成了诱导期。诱导治疗完成后重复进行骨髓研究,并观察到缓解模式。结果:完成化疗的157例患者中,有137例(87%)完全缓解(<5%骨髓中成骨细胞),14例(9%)完全缓解。进入部分缓解(骨髓中5--25%的胚细胞),有6个(4%)未缓解(骨髓中> 25%的胚细胞)。十名(5.5%)患者在诱导治疗过程中因出血,发热性中性粒细胞减少和败血症而死亡。结论:有效的化学疗法可治愈儿童的ALL。贫穷,无知和对结果的误解是导致孟加拉国等第三世界国家拒绝和停止化疗的原因。通过改善隔离,障碍护理和支持治疗的设施以及提高认识,可以降低死亡率和治疗费用。JEnam Med Col 2017; 7(1):25-28

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号